The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with leukemia and lymphoma. To achieve this objective, results of laboratory studies will be used to provide the basis for development of new treatment approaches in the clinic. Important for the success of this project is the biostatistical collaboration with individuals in this Core who provide computerized entry and quality assurance of data, and assist in the design and analysis of clinical, laboratory, and animal research projects. The purpose of the Biostatistics Core is to provide the following services that will be utilized by all of the research projects. 1. To provide biostatistical collaboration for clinical research protocols. This includes all aspects of the design, conduct, analysis, and reporting of the clinical protocols. 2. To provide biostatistical collaboration for animal and laboratory research studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, including the coordination of laboratory results with parameters and outcomes from the clinical studies. 3. To supervise data processing and data quality assurance, and to coordinate the efforts of the data specialist and those of the data managers in maintaining an accurate computerized database. 4. To provide a data specialist to maintain a computerized database, with assured quality control and standardized reporting. 5. To provide computing resources for data processing, forms design, and statistical analyses. 6. To periodically review the function of the tracking process, to insure that specimens are being received and distributed in a timely fashion. 7. To assure computerized recording of laboratory results on research specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-05
Application #
6314047
Study Section
Project Start
2000-05-10
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$226,134
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Bolin, Sara; Borgenvik, Anna; Persson, Camilla U et al. (2018) Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 37:2850-2862
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117

Showing the most recent 10 out of 376 publications